- Home
- BEAT vs PRLD Comparison
BEAT vs PRLD Comparison
Compare BEAT & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEAT
- PRLD
- Stock Information
- Founded
- BEAT 2015
- PRLD 2016
- Country
- BEAT United States
- PRLD United States
- Employees
- BEAT N/A
- PRLD N/A
- Industry
- BEAT Retail: Computer Software & Peripheral Equipment
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- BEAT Technology
- PRLD Health Care
- Exchange
- BEAT Nasdaq
- PRLD Nasdaq
- Market Cap
- BEAT 65.1M
- PRLD 73.7M
- IPO Year
- BEAT 2021
- PRLD 2020
- Fundamental
- Price
- BEAT $2.08
- PRLD $0.87
- Analyst Decision
- BEAT Buy
- PRLD Strong Buy
- Analyst Count
- BEAT 1
- PRLD 2
- Target Price
- BEAT $8.00
- PRLD $4.50
- AVG Volume (30 Days)
- BEAT 131.3K
- PRLD 196.9K
- Earning Date
- BEAT 03-19-2025
- PRLD 03-04-2025
- Dividend Yield
- BEAT N/A
- PRLD N/A
- EPS Growth
- BEAT N/A
- PRLD N/A
- EPS
- BEAT N/A
- PRLD N/A
- Revenue
- BEAT N/A
- PRLD $3,000,000.00
- Revenue This Year
- BEAT N/A
- PRLD N/A
- Revenue Next Year
- BEAT N/A
- PRLD N/A
- P/E Ratio
- BEAT N/A
- PRLD N/A
- Revenue Growth
- BEAT N/A
- PRLD N/A
- 52 Week Low
- BEAT $1.35
- PRLD $0.80
- 52 Week High
- BEAT $3.48
- PRLD $6.80
- Technical
- Relative Strength Index (RSI)
- BEAT 39.34
- PRLD 37.59
- Support Level
- BEAT $2.05
- PRLD $0.87
- Resistance Level
- BEAT $2.37
- PRLD $1.01
- Average True Range (ATR)
- BEAT 0.18
- PRLD 0.08
- MACD
- BEAT -0.02
- PRLD -0.02
- Stochastic Oscillator
- BEAT 21.24
- PRLD 0.90
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.